hrp0098p2-227 | Pituitary, Neuroendocrinology and Puberty | ESPE2024

Real Life Efficacy and Safety of Monthly (4-week) and 6-Monthly (24-week) Formulations of Gonadotropin-Releasing Hormone Agonist (GnRHa) Among Children with Central Precocious and Early Fast Puberty

Shopen Libby , Dror Nitzan , Eliakim Alon , Rachmiel Marianna , Barash Galia

Background: Central precocious puberty (CPP), early fast puberty (EFP) and early puberty (EP) are considered as deviations from normal variability of pubertal tempo. Gonadotropin releasing hormone agonists (GnRHa) have been considered the treatment of choice for CPP for decades, and later for EFP. Several pharmaceutical formulations of GnRHa have been developed, differing in the route and frequency of administration. Treatment was administered mainly by intra-...